In RCC patients, there is a shift from a type-1-mediated CD4+ T cell response producing IFNγ, which is critical for the development of effective antitumor immunity, to a type-2 cytokine IL-4, IL-5, and IL-10 response that typically mediates humoral immunity [65]. This evidence concerns the gene CD4 and renal cell carcinoma.